A true nerd of CGT

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Vincent, Founder and board chair at Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering: The days when CGT therapies were viewed as just academic... then the events in 2012 that changed everything in the space How partnering with Indiana University for its vector capacity led to the creation of Genezen Building a team that had been trained really well... by his wife! Looking for a PE company that brings more than just a fat cheque What’s next for the CGT sector after an over-hyped few years of fundraises... and what areas could be hot in the future Bill is the board chair of Genezen, a biotech contract manufacturer of viral vectors, cell manufacturing, and testing services. He founded the company fourteen years ago and grew it from his one-person operation to its current 60 employees with an outside investment of $45 million. He has spent the last 35 years working in the consumer products, pharma, and biotech sectors. Prior to Genezen, Bill was President and CEO at Rimedion, a gene therapy company developing treatments for rare genetic disorders. He currently serves on the board of Cellular Engineering Technologies, a stem cell services company. Bill discovered a passion for entrepreneurship through his exposure to new business development opportunities in a corporate setting. Upon completing his MBA at the University of Texas, he participated in a two-year executive development program with Philip Morris. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.